Medicare’s cheque matters more to Pacific Edge than any clinical trial

Pacific Edge has spent the better part of four years learning a lesson every New Zealand healthtech founder should tape to their monitor. In the US, good science gets you a meeting. Reimbursement gets you a business.

On 6 November the Dunedin cancer diagnostics company confirmed final Medicare coverage for its Cxbladder Triage and Triage Plus urine tests, at rates of US$1,057 and US$1,328 per test. Shares rose 8% on the day after a 9% lift the day before, as RNZ reported. The policy takes effect on 20 December.

This is a genuine win, and it deserves to be read as one.

Losing the biggest customer

Medicare was historically Pacific Edge’s largest US payer, and the company lost that coverage in April 2025 after a drawn-out review by contractor Novitas. The damage showed up quickly. In the year to March 2026, revenue nearly halved to NZ$11.5 million and the net loss widened to NZ$35.8 million, while total laboratory throughput fell 16.3% to 24,190 tests.

Nothing about the tests had changed. US urologists still wanted them. What vanished was certainty about who would pay, and in American healthcare that uncertainty is enough to stall a product that works.

The fight back took roughly four years and NZ$36.1 million of investor money. Chief executive Peter Meintjes has described it as “sprinting a marathon”.

A moat built from evidence

The detail that should excite investors most is not the price. It is that competing tests and generic billing codes are explicitly excluded from the new coverage determination. Pacific Edge is the only covered diagnostic under it.

That is not a handout. It is the payoff for doing the slow, expensive clinical and analytical validation work Medicare demands. BusinessDesk’s analysis suggests rivals could need five years or longer to catch up.

The company puts the opportunity at 1.14 million eligible testing opportunities a year among intermediate-risk microhaematuria patients. It will only win a share of that, but the bigger prize sits behind Medicare. Commercial insurers cover a further 223 million Americans and tend to follow Medicare’s lead, and Pacific Edge already has private contracts covering 12.9 million lives.

The backers who held their nerve

In May, Pacific Edge raised NZ$25.4 million on the strength of a draft decision, not a final one. Investors were betting on a regulatory timeline, not a scientific breakthrough. That bet now looks well placed.

Meintjes was blunt about why the higher-priced Triage Plus matters: “More revenue per test, more margin per test, higher margin percentage per test”. The shift is already under way. Triage Plus rose from under 1% of US tests in the June quarter to 10.8% in September alone, and a new Blue Cross Blue Shield contract in the Carolinas adds nearly 8 million covered lives from 1 November.

For the wider NZ medtech sector, this is the lesson. The risk that kills Kiwi exporters in regulated markets is rarely the science. It is the years spent waiting for a payer to say yes, with cash burning the whole time. Companies planning a US entry should budget for reimbursement as seriously as they budget for trials.

Now comes the sales grind

Meintjes is not pretending the job is done. “This is hand-to-hand combat,” he told BusinessDesk. “We have to increase volume, we have to increase customer stickiness. We have to improve the test per frontline salespeople, make sure our reps are effective, then we have to scale the number of reps.”

That realism is warranted. Net assets had shrunk to NZ$10.7 million by March, and US commercial volumes fell during the September quarter as the company deliberately trimmed spending while it waited. Execution, not regulation, is now the variable that matters.

The first full read on whether coverage converts into volume will come with FY27 results around May 2027. Until then, Pacific Edge has something it has lacked since 2025, a paying customer in the world’s most important healthcare market and a head start its competitors can’t buy. For a company that refused to give up, that is exactly the door it needed.

Sources

• ODT: Pacific Edge granted US Medicare coverage for cancer test (2026-11-06)
• RNZ: Shares in cancer diagnostics company Pacific Edge rise after Medicare coverage of tests (2026-11-06)
• BusinessDesk: Pacific Edge’s US test volumes fall, but lucrative Medicare coverage is imminent (2026-10-19)
• RNZ: Pacific Edge confident of return to profitability (2026-05-25)
• Pacific Edge: FY26 results – advancing Medicare coverage goals (2026-05-25)
• BusinessDesk: Pacific Edge back on track with restoration of US Medicare coverage (2026-11-06)
• NZX: Pacific Edge announcement – Medicare coverage confirmed (2026-11-06)
• NZX: Pacific Edge Q2 FY27 investor update – US commercial recovery (2026-10-19)